IDH1 mutant glioma is preferentially sensitive to the HDAC inhibitor panobinostat
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-7373
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
IDH1 mutant glioma is preferentially sensitive to the HDAC inhibitor panobinostat ; volume:154 ; number:2 ; day:23 ; month:8 ; year:2021 ; pages:159-170 ; date:9.2021
Journal of neuro-oncology ; 154, Heft 2 (23.8.2021), 159-170, 9.2021
- Creator
-
Sears, Thomas K.
Horbinski, Craig M.
Woolard, Kevin D.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s11060-021-03829-0
- URN
-
urn:nbn:de:101:1-2021112418434642218329
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:33 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Sears, Thomas K.
- Horbinski, Craig M.
- Woolard, Kevin D.
- SpringerLink (Online service)
Other Objects (12)
A vaccine targeting mutant IDH1 in newly diagnosed glioma
Investigating New Drug Options for Temozolomide Resistant IDH1 Mutant Glioma
5-Hydroxymethylcytosine preferentially targets genes upregulated in isocitrate dehydrogenase 1 mutant high-grade glioma
Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial
Current biomarker-associated procedures of cancer modeling-a reference in the context of IDH1 mutant glioma
Metabolic plasticity of IDH1-mutant glioma cell lines is responsible for low sensitivity to glutaminase inhibition
Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia
Biostructural, biochemical and biophysical studies of mutant IDH1
Author Correction: Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial
IDH1 mutation analysis – an example of putative glioma marker
The effects of BMP2 and the mechanisms involved in the invasion and angiogenesis of IDH1 mutant glioma cells
Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate
A vaccine targeting mutant IDH1 in newly diagnosed glioma
Investigating New Drug Options for Temozolomide Resistant IDH1 Mutant Glioma
5-Hydroxymethylcytosine preferentially targets genes upregulated in isocitrate dehydrogenase 1 mutant high-grade glioma
Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial
Current biomarker-associated procedures of cancer modeling-a reference in the context of IDH1 mutant glioma
Metabolic plasticity of IDH1-mutant glioma cell lines is responsible for low sensitivity to glutaminase inhibition
Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia
Biostructural, biochemical and biophysical studies of mutant IDH1
Author Correction: Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial
IDH1 mutation analysis – an example of putative glioma marker
The effects of BMP2 and the mechanisms involved in the invasion and angiogenesis of IDH1 mutant glioma cells
Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate
A vaccine targeting mutant IDH1 in newly diagnosed glioma
Investigating New Drug Options for Temozolomide Resistant IDH1 Mutant Glioma
5-Hydroxymethylcytosine preferentially targets genes upregulated in isocitrate dehydrogenase 1 mutant high-grade glioma
Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial
Current biomarker-associated procedures of cancer modeling-a reference in the context of IDH1 mutant glioma
Metabolic plasticity of IDH1-mutant glioma cell lines is responsible for low sensitivity to glutaminase inhibition
Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia
Biostructural, biochemical and biophysical studies of mutant IDH1
Author Correction: Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial
IDH1 mutation analysis – an example of putative glioma marker
The effects of BMP2 and the mechanisms involved in the invasion and angiogenesis of IDH1 mutant glioma cells